Benzonatate is NOT a scheduled controlled substance
Benzonatate is classified as a non-scheduled, non-narcotic antitussive medication by the DEA and FDA. 1
Key Regulatory Classification
Benzonatate has no DEA schedule classification because it is not considered a controlled substance. The FDA drug label explicitly describes it as a "non-narcotic oral antitussive agent" 1. This distinguishes it from opioid-based cough suppressants like codeine (Schedule II-V depending on formulation) or hydrocodone (Schedule II).
Clinical Context
While benzonatate lacks abuse potential warranting DEA scheduling, this does not mean it is without significant safety concerns:
Critical Safety Warnings:
- Severe toxicity can occur with overdose, including seizures, cardiac arrest, and death—sometimes within 15-20 minutes of ingestion 1
- Accidental pediatric ingestion has resulted in deaths in children under age 10 1
- The medication must be swallowed whole; chewing or dissolving capsules can cause dangerous local anesthesia of the oral mucosa and choking 1
Prescribing Implications
Because benzonatate is non-scheduled:
- No special DEA registration or prescription requirements apply
- Standard prescription practices are sufficient
- Maximum recommended dosing is 200 mg per dose, 600 mg daily 1
The lack of scheduling reflects its mechanism as a peripherally-acting local anesthetic on stretch receptors 2 rather than central opioid receptor activity. However, its sodium channel blocking properties can cause life-threatening toxicity in overdose 3, 4, warranting careful patient counseling about proper use and storage away from children.